Search URGN
UroGen Pharma Ltd.
Nasdaq · CIK 1668243
Last close41.4
Daily change+0.85 (2.10%)
10 Years gain+196.14%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
URGN · STANDARD
SIC 2834 · Pharmaceutical Preparations · Fiscal year end 1231
Fundamental
64.9Momentum
n/aAcceleration
n/aConfidence
68.0Annual Revenue10
Quarterly Revenue34
Annual CFO10
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth21.9 / 25
Quality10.1 / 25
Capital Efficiency20.0 / 20
Balance Sheet9.7 / 15
Shareholder Economics0.0 / 10
Forward Indicators0.0 / 5
Signals
Gross margin expansionGross margin improved by 0.2656 percentage points.
Warnings
Receivables anomaly · MEDIUMAccounts receivable growth is materially above revenue growth.
Inventory anomaly · MEDIUMInventory growth is materially above revenue growth.
Possible growth trap · HIGHRevenue growth is high, but quality indicators are deteriorating.
Key Metrics
Revenue Growth TTM85.13%OK
Revenue CAGR 3Y19.49%OK
Gross Margin89.98%OK
Operating Margin-50.82%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROICn/aMISSING
Incremental Operating Margin 3Yn/aNOT_MEANINGFUL
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Yn/aINSUFFICIENT_HISTORY
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $109.79M | $97.34M | -$124.86M | -$162.44M | -$162.73M | 88.66% | -113.73% | -148.22% | n/a | n/a |
| 2025 FY Dec 31, 2024 | $90.40M | $81.52M | -$96.78M | -$96.77M | -$97.06M | 90.18% | -107.06% | -107.37% | n/a | n/a |
| 2024 FY Dec 31, 2023 | $82.71M | $73.35M | -$65.54M | -$76.38M | -$76.57M | 88.68% | -79.23% | -92.57% | n/a | n/a |
| 2023 FY Dec 31, 2022 | $64.36M | $56.70M | -$79.04M | -$87.56M | -$87.81M | 88.11% | -122.82% | -136.45% | n/a | n/a |
| 2022 FY Dec 31, 2021 | $48.04M | $42.89M | -$92.29M | -$84.89M | -$85.64M | 89.27% | -192.11% | -178.27% | n/a | n/a |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $175.11M | sum latest 4 fiscal quarters Revenue | OK | 0001437749-26-025794, 0001437749-25-033468 |
| Revenue Growth TTM | 85.13% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001437749-26-025794, 0001437749-25-033468 |
| Revenue CAGR 3Y | 19.49% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001437749-26-006234 |
| Revenue CAGR 5Y | 56.22% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001437749-26-006234 |
| Gross Profit CAGR 3Y | 19.74% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001437749-26-006234 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001437749-26-025794, 0001437749-25-033468 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 89.98% | Gross Profit / Revenue | OK | 0001437749-26-025794, 0001437749-25-033468 |
| Operating Margin | -50.82% | Operating Income / Revenue | OK | 0001437749-26-025794, 0001437749-25-033468 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001437749-26-025794 |
| Current Ratio | 3.8x | Current Assets / Current Liabilities | OK | derived |
| Cash / Debt | 0.55x | (Cash + Short-term Investments) / Total Debt | OK | 0001437749-26-025794 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |
| Dividend Payout Ratio | n/a | Cash dividends paid / Net income | NOT_MEANINGFUL | 0001437749-26-006234 |